Cargando…

Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy

Co-delivery nanoparticles with characteristics of intracellular precision release drug have been generally accepted as an effective therapeutic strategy for eye diseases. In this study, we designed a new co-delivery system (miRNA/NP-BRZ) as a lasting therapeutic approach to prevent the neuro-destruc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tingting, Wang, Ye, Chen, Jiahao, Gao, Xiaoshu, Pan, Siqi, Su, Yu, Zhou, Xinrong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067192/ https://www.ncbi.nlm.nih.gov/pubmed/32133894 http://dx.doi.org/10.1080/10717544.2020.1731861

Ejemplares similares

Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension
por: Gandolfi, Stefano A., et al.
Publicado: (2014)

The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients
por: Onoe, Hiromitsu, et al.
Publicado: (2022)

Brinzolamide/Brimonidine Fixed Combination: Simplifying Glaucoma Treatment Regimens
por: Moosavi, Reza, et al.
Publicado: (2018)

Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
por: Wang, Ningli, et al.
Publicado: (2020)

Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus
por: Nguyen, Quang H
Publicado: (2014)

The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
por: Onoe, Hiromitsu, et al.
Publicado: (2021)

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost
por: Nakamura, Yoshimi, et al.
Publicado: (2009)

Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension
por: Whitson, Jess T, et al.
Publicado: (2013)

Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension
por: Syed, Misha F, et al.
Publicado: (2011)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
por: Lerner, S Fabián, et al.
Publicado: (2019)

Fixed-combination brinzolamide 1%/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies
por: Realini, T, et al.
Publicado: (2013)

A novel ocular delivery of brinzolamide based on gellan gum: in vitro and in vivo evaluation
por: Sun, Jingfen, et al.
Publicado: (2018)

Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension
por: Iester, Michele
Publicado: (2008)

Safety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma
por: Hommer, Anton, et al.
Publicado: (2015)

miRNA-124 in Immune System and Immune Disorders
por: Qin, Zhen, et al.
Publicado: (2016)

Chitosan Hydrogel Doped with PEG-PLA Nanoparticles for the Local Delivery of miRNA-146a to Treat Allergic Rhinitis
por: Su, Yu, et al.
Publicado: (2020)

A Novel Ocular Delivery of Brinzolamide Based on Gellan Gum: In vitro and in vivo Evaluation [Retraction]
Publicado: (2022)

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
por: Lorenz, Katrin, et al.
Publicado: (2011)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension
por: Yoshikawa, Keiji, et al.
Publicado: (2014)

Clinical effectiveness of brinzolamide 1%–brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension
por: Sharma, Sourabh, et al.
Publicado: (2015)

Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension
por: Topouzis, Fotis, et al.
Publicado: (2019)

Mechanisms Contributing to the Dysregulation of miRNA-124 in Pulmonary Hypertension
por: Zhang, Hui, et al.
Publicado: (2021)

Brinzolamide-timolol suspension: acceptability and side effect profile
por: Doherty, MD, et al.
Publicado: (2011)

Crystal structure of Brinzolamide: a carbonic anhydrase inhibitor
por: Zheng, Huirong, et al.
Publicado: (2016)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/timolol among patients with open-angle glaucoma or ocular hypertension
por: Sanseau, Ana, et al.
Publicado: (2013)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension [Erratum]
Publicado: (2014)

Safety and efficacy of a fixed versus unfixed brinzolamide/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension
por: Nagayama, Mikio, et al.
Publicado: (2014)

Patient perspectives when switching from Cosopt(®) (dorzolamide-timolol) to Azarga™ (brinzolamide-timolol) for glaucoma requiring multiple drug therapy
por: Auger, Graham Anthony, et al.
Publicado: (2012)

Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis
por: Liu, Yuanzhi, et al.
Publicado: (2019)

Identification of Candidate miRNA Biomarkers for Glaucoma
por: Hindle, Allyson G., et al.
Publicado: (2019)

Formulation Development and Evaluation of the Therapeutic Efficacy of Brinzolamide Containing Nanoemulsions
por: Mahboobian, Mohammad Mehdi, et al.
Publicado: (2017)

Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients
por: Ishikawa, Makoto, et al.
Publicado: (2009)

Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
por: Beckers, Henny JM, et al.
Publicado: (2009)

A comparative study on efficacy of fixed combination timolol/brinzolamide versus travoprost monotherapy in drug-naïve open-angle glaucoma patients
por: Dixit, Alok, et al.
Publicado: (2020)

Ocular Distribution of Brimonidine and Brinzolamide after Topical Instillation of a 0.1% Brimonidine Tartrate and 1% Brinzolamide Fixed-Combination Ophthalmic Suspension: An Interventional Study
por: Orii, Yusuke, et al.
Publicado: (2023)

Cationic Polymer Nanoparticles-Mediated Delivery of miR-124 Impairs Tumorigenicity of Prostate Cancer Cells
por: Conte, Raffaele, et al.
Publicado: (2020)

Correlation between miRNA-124, miRNA-544a, and TNF-α levels in acute spinal cord injury
por: Ma, Xiaomin, et al.
Publicado: (2022)

Phase III safety and efficacy study of long-term brinzolamide/timolol fixed combination in Japanese patients with open-angle glaucoma or ocular hypertension
por: Nakajima, Masayuki, et al.
Publicado: (2014)

Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
por: Altafini, Romeo, et al.
Publicado: (2015)

Efficacy and safety of a fixed combination of 1% brinzolamide and 0.1% brimonidine as treatment for glaucoma: a retrospective study focusing on the number of ingredients
por: Aoki, Ryota, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bsr4anq1jidoevermie7m0ne26